|[September 26, 2013]
New Links between Depression and Inflammatory Conditions Explored at 2013 U.S. Psychiatric and Mental Health Congress
LAS VEGAS --(Business Wire)--
The 26th Annual U.S.
Psychiatric and Mental Health Congress Conference and Exhibition,
taking place September 30 - October 3 in Las Vegas, will feature two
unique presentations focused on exploring depression and
patient-specific treatment response factors.
In a poster presentation titled, Clinical Effect of
L-methylfolate in Patients Stratified by Baseline Obesity and
Inflammation : a Randomized Clinical Trial of Patients with Major
Depression, on October 1st at 2:00pm, Dr. Charles Raison,
Associate Professor, Department of Psychiatry, University of Arizona
School of Medicine, will discuss the findings of a multi-center,
double-blind, placebo-controlled trial that identified correlations
between L-methylfolate and antidepressant response in patients
presenting with certain conditions, such as inflammation and obesity.
The study focused on 75 inadequate responders to SSRIs who were enrolled
in a 60-day, multi-center, double-blind, placebo-controlled trial.
Patients were given 15 mg/day of L-methylfolate for 60 days, placebo for
30 days followed by L-methylfolate 15 mg/day for 30 days, or placebo for
60 days. Results reported in the American Journal of Psychiatry revealed
that inadequate responders (all-comers) given adjunctive L-methylfolate
had significantly greater response and reduction in depressive symptoms
than adjunctive placebo (SSRI monotherapy). In an exploratory analysis,
a subgroup of patients with a baseline BMI of 30 or greater and hsCRP
above the median responded even more robustly to adjunctive
L-methylfolatethan did all-comers. It was concluded that the presence
of obesity and inflammation in individuals with depression may predict
greater response to SSRI therapy augmented with L-methylfolate.
"This data is teaching us more about how biomarkers might be used to
advance treatment strategies in depression," said Dr. Raison. "This
information is helping clinicians understand how to better select
therapeutic options based on a patient's underlying biological
conditions. As we continue to explore these findings, future
developments will no doubt continue to deliver advancements in the
treatment of depression."
Conference attendees will also have the opportunity to attend a
Continuing Medical Education (CME) Symposium session titled, The
Emerging Role of L-methylfolate in Depression: When, Where, and Why?
Focus on Obesity, Inflammation, and Genetic Factors.
The CME, taking place September 30th at 12:00pm, aims to help
clinicians explore genetic, metabolic and inflammatory markers that may
assist in the selection of treatment options in Major Depressive
Pamlab, founded in 1987, is a specialty biomedical company that
specializes in offering high quality prescription medical foods to
safely and effectively address the distinct nutritional requirements of
patients with specific medical conditions. Pamlab investigates
nutritional science and promotes evidence which can direct effective
disease management for brain health (depression and memory loss) and
metabolic conditions (diabetes). Pamlab, part of Nestlé Health Science
since April 2013, employs around 450 people in the United States and is
based in Covington, Louisiana. More information is available at www.pamlab.com.
About Nestlé Health Science
Nestlé Health Science, a wholly-owned subsidiary of Nestlé, intends to
spearhead the development of science-based personalized nutritional
solutions. Building on its core HealthCare Nutrition business, the
company has ambitions to address chronic conditions in the area of
Gastrointestinal Health, Metabolic Health and Brain Health. Nestlé
Health Science offers nutritional solutions for people with specific
dietary needs related to illnesses, disease states or the special
challenges of different life stages. Nestlé Health Science employs
around 3,000 people worldwide and has its headquarters in Vevey,
Switzerland. For more information, please visit www.nestlehealthscience.com.
About U.S. Psych Congress
The U.S. Psychiatric and Mental Health Congress (Psych Congress) was
established as an educational platform where experts in the mental
health field can explore cutting-edge science, share comprehensive best
practices and generate stimulating discussion. Psych Congress is focused
on thinking forward, providing attendees with advanced knowledge and
unique tools from which they can confidently diagnose and develop
effective individualized treatment plans, by applying evidence-based
management into daily practice.
[ Back To Technology News's Homepage ]